Local Business
15520018 · located on
USAspending.gov — federal awards · lists
{
"id": "atm_ovt_8b388c11_e6e1_4a25_b45e_02673c5b3e66",
"kind": "LocalBusiness",
"name": "Kalytera Therapeutics Delaware , Inc",
"parent_id": "atm_geoid_060411060012011",
"depth": null,
"facts": {
"address": "4040 Civic Center Dr",
"sources": [
{
"between": null,
"dataset": "BrightQuery",
"license": "CDLA-Permissive-2.0",
"version": "2026-09-08",
"property": "",
"provider": "brightquery",
"resource": "brightquery",
"record_id": "371637364",
"confidence": 0.95,
"update_time": "2026-09-17T20:01:51.007Z"
},
{
"between": null,
"dataset": "Overture",
"license": "CDLA-Permissive-2.0",
"version": "2026-09-17",
"property": "/properties/confidence",
"provider": "overture",
"resource": "confidence_calculation",
"record_id": null,
"confidence": null,
"update_time": "2026-09-17T22:52:12Z"
}
],
"category": "b2b_scientific_lab",
"locality": "San Rafael",
"postcode": "94903-4150",
"websites": [
"www.claritaspharma.com"
],
"hierarchy": [
"services_and_business",
"b2b_service",
"b2b_science_and_technology_service",
"b2b_scientific_lab"
],
"confidence": 0.95,
"overture_id": "8b388c11-e6e1-4a25-b45e-02673c5b3e66",
"basic_category": "b2b_science_and_technology_service",
"operating_status": "permanently_closed",
"overture_release": "2026-09-23.1"
},
"source_id": "src_ea62d6013cef6e1e92b7",
"updated_at": "2026-10-10T02:29:06.946Z",
"type": "Feature",
"geometry": {
"type": "Point",
"coordinates": [
-122.538897,
38.006676
]
},
"links": {
"self": "https://miscsubjects.com/atlas/atoms/atm_ovt_8b388c11_e6e1_4a25_b45e_02673c5b3e66",
"children": "https://miscsubjects.com/atlas/atoms/atm_ovt_8b388c11_e6e1_4a25_b45e_02673c5b3e66/children",
"descendants": "https://miscsubjects.com/atlas/atoms/atm_ovt_8b388c11_e6e1_4a25_b45e_02673c5b3e66/descendants",
"inside": "https://miscsubjects.com/atlas/atoms/atm_ovt_8b388c11_e6e1_4a25_b45e_02673c5b3e66/inside",
"graph": "https://miscsubjects.com/atlas/graph?start=atm_ovt_8b388c11_e6e1_4a25_b45e_02673c5b3e66"
},
"ancestors": [
{
"id": "atm_geoid_060411060012011",
"kind": "CensusBlock",
"name": "Block 2011",
"up": 1
},
{
"id": "atm_geoid_060411060012",
"kind": "CensusBlockGroup",
"name": "Block Group 2",
"up": 2
},
{
"id": "atm_geoid_06041106001",
"kind": "CensusTract",
"name": "Census Tract 1060.01",
"up": 3
},
{
"id": "atm_geoid_06041",
"kind": "County",
"name": "Marin County",
"up": 4
},
{
"id": "atm_geoid_06",
"kind": "State",
"name": "California",
"up": 5
},
{
"id": "atm_geoid_us",
"kind": "Country",
"name": "United States",
"up": 6
}
],
"children_by_kind": [],
"edges_out": [
{
"rel": "located_on",
"id": "atm_marin_parcels_2514014",
"kind": "Parcel",
"name": "15520018",
"share": null
}
],
"edges_in": [
{
"rel": "lists",
"id": "atm_site_6430e240d61fcd496457",
"kind": "GovernmentWebsite",
"name": "USAspending.gov — federal awards",
"share": null
}
],
"edges_in_total": 1,
"external_ids": [
{
"system": "overture_gers",
"value": "8b388c11-e6e1-4a25-b45e-02673c5b3e66"
}
],
"source": {
"id": "src_ea62d6013cef6e1e92b7",
"url": null,
"license": "Overture Maps Foundation 2026-09-23.1: places CDLA-Permissive 2.0 / ODbL for OSM-derived; buildings and addresses ODbL / CDLA-P; divisions and transportation ODbL (https://docs.overturemaps.org/attribution/)",
"read_at": "2026-10-10T02:27:22.458Z",
"sha256": "af0a59a33d2a75cacc7cf95f854d2f1af02bfaffbfc955875480f1b30e380665"
},
"observations": [
{
"service": "WEBSITE_EXTRACT",
"fetched_at": {},
"query": {
"job": "website:atm_ovt_8b388c11_e6e1_4a25_b45e_02673c5b3e66",
"url": "https://www.claritaspharma.com/"
},
"payload": {
"title": "Claritas Pharmaceuticals - Fighting vaccine-resistant COVID strains",
"emails": [],
"jsonld": [
{
"url": "https://claritaspharma.com/",
"name": "Claritas Pharmaceuticals",
"@type": "WebSite",
"@context": "https://schema.org/",
"potentialAction": {
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://claritaspharma.com/search/%7Bsearch_term_string%7D/"
},
"query-input": "required name=search_term_string"
}
},
{
"url": "https://claritaspharma.com/",
"logo": "https://claritaspharma.com/wp-content/uploads/2023/10/favicon.png",
"name": "Claritas Pharmaceuticals",
"@type": "Organization",
"@context": "https://schema.org/"
}
],
"phones": [],
"public": true,
"sha256": "e6ee6ab9774312d29afdfde506d38f56b7e391843c6c7bf9725406899b597341",
"excerpt": " Claritas Pharmaceuticals - Fighting vaccine-resistant COVID strains Skip to content Claritas Pharmaceuticals Fighting vaccine-resistant COVID strains Menu Close Home Our Company Partnering Team Overview Chairman’s Blog Products in Development R-107 for ARDS R-107 for COVID-Related Sepsis R-107 for Neonatal Patients R-107 for PAH R-107 for PPHN Our Science Nitric Oxide Technology Anti-COVID Technology Technology for Treatment of Pain For Investors Investor Relations Stock Quote SEDAR Filings Press Releases FAQ Contact us Full 2 Special Emphasis on Neonatal Market NITRIC OXIDE-RELEASING COMPOUND FOR TREATMENT OF LUNG DISEASE Read more Full 2 Our Mission Our daily motivation is to defeat vaccine-resistant COVID-19 infection Read more Full 2 Our Company Experienced scientists doing pioneering research supported by funding from the National Institutes of Health (NIH) and the U.S. Advanced Biomedical Research and Development Agency (BARDA) Read more Full 2 Our Science Claritas is designing and developing drugs to work in harmony with the body's natural defense mechanisms to hasten and strengthen the body's reaction to infections and other disorders Read more Nitric Oxide Technology Claritas Pharmaceuticals is an innovative biotech company developing R-107 for the treatment of vaccine-resistant COVID strains. Our scientific team has built a reputation for global leadership in basic science, drug development, and clinical medicine. Our expertise and professional network enable us to create groundbreaking opportunities that tackle drug development challenges. R-107 was designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. Without a functional spike protein, the virus is rendered harmless due to its inability to enter and infect cells. Vaccines may fail when new mutations in the spike protein arise, but R-107 and the nitric oxide payload that it delivers will continue to render the virus harmless–regardless of how it may mutate. > R-107 for Covid & Viral Infections > R-107 and Vaccines > Nitric Oxide Technology A message from our Chairman, Robert Farrell “I am often asked why we are focusing on nitric oxide as a treatment for coronavirus. The answer is simple: because we know it works.” 2 Lead Compounds $25M Research Funding From The NIH And BARDA 2 Targeted Diseases 1 Billion People Affected By Targeted Diseases read more Class Acceleration Corp. A (CLAS:CA) Go to Stock Watch Quick links Press Releases Investor Relations FAQ Stay Connected Receive breaking news first subscribe Press Releases 11 Oct Kalytera Therapeutics Inc. Completes Name Change to Claritas Pharmaceuticals, Inc Company to Hold Annual and Special Meeting on June 17, 2021 SAN FRANCISCO, CA — (Apri... 11 Oct Claritas Pharmaceuticals Issues Letter to Shareholders SAN FRANCISCO, CA and TORONTO, ON — (May 11, 2021) – Claritas Pharmaceuticals, Inc. (TSX VEN... 11 Oct Claritas Pharmaceuticals (formerly Kalytera Therapeutics) to Focus on Development of R-107 as a Therapy for Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections SAN FRANCISCO, CA and TORONTO, ON — (March 1, 2021) – Claritas Pharmaceuticals, Inc. (former... 11 Oct Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries SAN FRANCISCO, CA and TORONTO, ON — (January 4, 2022) – Claritas Pharmaceuticals, Inc. (TSX ... Our Company Partnering Team Overview Chairman’s Blog For Investors Investor Relations Stock Quote SEDAR Filings Press Releases FAQ Products in Development R-107 for ARDS R-107 for COVID-Related Sepsis R-107 for Neonatal Patients R-107 for PAH R-107 for PPHN Our Science Nitric Oxide Technology Anti-COVID Technology Technology for Treatment of Pain Data privacy | Cookie Policy © Copyright 2026 Claritas Pharmaceuticals ",
"source_url": "https://claritaspharma.com/",
"observed_at": "2026-10-13T20:49:07.853Z"
}
}
],
"edges_out_total": 1
}